Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1493378
PUBLISHER: Grand View Research | PRODUCT CODE: 1493378
U.S. Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Liver Cancer Diagnostics Market Growth & Trends:
The U.S. liver cancer diagnostics market is anticipated to reach USD 4.37 billion by 2030, exhibiting a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is attributable to the increasing prevalence of liver cancer, rising prevalence of risk factors for liver cancer, and technological advancements. The significant prevalence of liver cancer in the country highlights the need for its prevention, detection, and treatment. For instance, liver and intrahepatic bile duct cancer accounted for 2.2% of all new cancer cases in 2022.
Moreover, the growing number of government programs and collaborative efforts to transform cancer prevention, detection, treatment, and research in the country through substantial investments, data-driven approaches, and nationwide collaborations are further expected to propel market growth. For instance, the Translational Liver Cancer (TLC) Consortium, established by the National Cancer Institute's (NCI) Division of Cancer Prevention, aims to advance translational research specifically focused on improving surveillance, early detection, and risk stratification of liver cancer.
The Cancer Moonshot initiative initiated in February 2022 highlights the importance of collaborative efforts in advancing cancer research, treatment, and patient care. A significant investment of USD 240 million in the Cancer Moonshot supports new ways to prevent, detect, treat, and survive cancer. This funding is likely channeled through the Advanced Research Projects Agency for Health (ARPA-H) to researchers and innovators working on cancer-related projects. The investment includes initiatives such as developing tools for early cancer detection, innovative approaches for visualizing cancer cells during surgery, novel treatment methods like using bacteria to target cancer cells and designing devices for more effective tumor treatment.
U.S. Liver Cancer Diagnostics Market Report Highlights:
- In terms of end-use, the hospitals and diagnostic laboratories segment dominated the market with the highest share of around 50%. This high share is attributable to the significant presence of hospitals across the country.
- Based on test type, the molecular markers segment is expected to grow at the fastest CAGR of 9.9% over the forecast period owing to the recent developments in the discovery of novel biomarkers for cancer research and diagnosis.
- The laboratory tests segment accounted for the largest revenue share of around 40% in 2023 due to their ability to detect biomarkers, facilitate early detection, and provide prognostic information in cancer diagnosis.
- In Jan 2023, Amy Kim and her team from Johns Hopkins Medicine developed a new screening test for liver cancer, which uses urine to isolate complementary tumor DNA for cancer detection.
Product Code: GVR-4-68040-290-2
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Test Type
- 1.2.2. End-use
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Test type outlook
- 2.2.2. End-use outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Liver Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Liver Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's Five Forces
Chapter 4. U.S. Liver Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
- 4.1. Test Type Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. U.S. Liver Cancer Diagnostics Market by Test Type Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Laboratory Tests
- 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2. Biomarker Tests
- 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2.2. Oncofetal And Glycoprotein Antigens
- 4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2.3. Enzymes And Isoenzymes
- 4.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2.4. Growth Factors and Receptors
- 4.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2.5. Molecular Markers
- 4.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.2.6. Pathological Biomarkers
- 4.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1.3. Blood Tests
- 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Imaging
- 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Endoscopy
- 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Biopsy
- 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1. Laboratory Tests
Chapter 5. U.S. Liver Cancer Diagnostics Market: End-use Estimates & Trend Analysis
- 5.1. End-use Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. U.S. Liver Cancer Diagnostics Market by End-use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Hospitals and Diagnostic Laboratories
- 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Academic and Research Institutes
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Pharmaceutical and CRO Laboratories
- 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.1. Hospitals and Diagnostic Laboratories
Chapter 6. U.S. Liver Cancer Diagnostics Market: Region Estimates & Trend Analysis
- 6.1. Regional Market Share, 2023 & 2030
- 6.2. U.S. Liver Cancer Diagnostics Market by Region Outlook
- 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
- 6.3.1. West
- 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Midwest
- 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. Northeast
- 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Southwest
- 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.5. Southeast
- 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.1. West
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company heat map analysis, 2023
- 7.4. Company Profiles
- 7.4.1. Abbott Laboratories
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Guardant Health
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Thermo Fisher Scientific, Inc.
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. Illumina, Inc.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. F.Hoffmann-La Roche Ltd.
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. Qiagen N.V.
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Siemens Healthineers
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. Becton, Dickinson & Company
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Epigenomics AG
- 7.4.9.1. Company overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
- 7.4.10. Koninklijke Philips N.V.
- 7.4.10.1. Company overview
- 7.4.10.2. Financial performance
- 7.4.10.3. Product benchmarking
- 7.4.10.4. Strategic initiatives
- 7.4.11. FUJIFILM Healthcare Americas Corporation
- 7.4.11.1. Company overview
- 7.4.11.2. Financial performance
- 7.4.11.3. Product benchmarking
- 7.4.11.4. Strategic initiatives
- 7.4.1. Abbott Laboratories
Product Code: GVR-4-68040-290-2
List of Tables
- Table 1 List of abbreviations
- Table 2 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
- Table 3 U.S. liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
- Table 4 U.S. liver cancer diagnostics, by region, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 U.S. liver cancer diagnostics market: market outlook
- Fig. 9 U.S. liver cancer diagnostics market competitive insights
- Fig. 10 Parent market outlook
- Fig. 11 Related/ancillary market outlook
- Fig. 12 Penetration and growth prospect mapping
- Fig. 13 U.S. liver cancer diagnostics market driver impact
- Fig. 14 U.S. liver cancer diagnostics market restraint impact
- Fig. 15 U.S. liver cancer diagnostics: Test type movement analysis
- Fig. 16 U.S. liver cancer diagnostics: Test type outlook and key takeaways
- Fig. 17 Laboratory tests market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 18 Biomarker tests market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 19 Oncofetal and glycoprotein antigens market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 20 Enzymes and isoenzymes market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 21 Growth factors and receptors market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 22 Molecular markers market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 Pathological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 24 Blood tests market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 25 Imaging market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 26 Endoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 27 Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 28 U.S. liver cancer diagnostics: End-use movement analysis
- Fig. 29 U.S. liver cancer diagnostics: End-use outlook and key takeaways
- Fig. 30 Hospitals and diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 31 Academic and research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 32 Pharmaceutical and CRO laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 33 U.S. liver cancer diagnostics market: Regional movement analysis
- Fig. 34 U.S. liver cancer diagnostics market: Regional outlook and key takeaways
- Fig. 35 West market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 36 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 37 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 38 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 39 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.